protein kinase D2Genealiases: HSPC187 · PKD2 · nPKC-D2
Q-omics provides the consensus-scored PRKD2 profile across patient tissues and cancer cell-line models. PRKD2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PRKD2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PRKD2 protein abundance shows 32,050 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where PRKD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKD2 survival associations across molecular data types. PRKD2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKD2 RNA expression–survival associations across cancer types. High PRKD2 expression shows unfavorable associations in ACC, LGG, KIRP and OV, but favorable associations in BLCA and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PRKD2 RNA expression.
This table summarizes PRKD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKD2 shows higher tumor expression in KIRC, HNSC, BLCA, LIHC, THCA and STAD. The KIRC box plot shows higher PRKD2 RNA expression in tumor versus normal tissue (log2 FC = +0.903, t-test p < 0.001).
This table shows molecular features associated with PRKD2 in patient tissues and cancer cell lines. In patient samples, PRKD2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
